// App-Quantinova.ai

POS03 : Everolimus-eluting bioabsorbable vascular scaffold and personalised platelet inhibition: no scaffold thrombosis in a single-centre registry with 223 consecutive patients

Researchers

Presenter

  • Christ G

Principal Investigators

  • Hafner T

  • Francesconi M

  • Podczeck-Schweighofer A

Medical Centers

  • Kaiser Franz Josef Hospital, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Ticagrelor

  • Adenosine

  • Adenosine Intravenous

  • Prasugrel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved